Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib-Reference-Cited by-同舟云学术

Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib

Published:2022-05 Issue:9 Volume:14 Page:507-517
ISSN:1750-1911
Container-title:Epigenomics
language:en
Short-container-title:Epigenomics

Author:

Salani Francesca¹²³^ORCID,Latarani Maryam²^ORCID,Casadei-Gardini Andrea⁴^ORCID,Gangadharannambiar Priyadarsini²,Fornaro Lorenzo⁵^ORCID,Vivaldi Caterina⁶^ORCID,Pecora Irene⁷^ORCID,Massa Valentina³,Marisi Giorgia⁸^ORCID,Canale Matteo⁸^ORCID,Ulivi Paola⁸^ORCID,Scartozzi Mario⁹^ORCID,Eccleston Mark¹⁰,Masi Gianluca⁶^ORCID,Crea Francesco²^ORCID

Affiliation:

1. Sant'Anna School of Advanced Studies, Institute of Life Sciences, Piazza Martiri della Libertà 33, Pisa, 56124, Italy

2. Cancer Research Group-School of Life Health and Chemical Sciences, The Open University, Milton Keynes, MK7 6AA, UK

3. Medical Oncology Department, Pisa University, Via Savi 10, Pisa, 56126, Italy

4. Department of Oncology, Vita-Salute San Raffaele University, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute Hospital, Milan, Italy

5. Medical Oncology Department, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56100, Pisa

6. Department of Translational Research and New Technologies for Medicine and Surgery, University of Pisa, Via Savi 10, Pisa, 56126, Italy

7. Unit of Medical Oncology, Ospedale Misericordia di Grosseto,Via Senese, 161, Grosseto, 58100, Italy

8. Biosciences Laboratory, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Romagnolo per lo Studio dei Tumori ‘Dino Amadori,’ Meldola, 47014, Italy

9. Department of Medical Sciences and Public Health, University of Cagliari, Via Università, 40, Cagliari CA, 09124, Italy

10. Belgian Volition SPRL, Parc Scientifique Créalys, Rue Phocas Lejeune 22, Isnes, BE, 5032, Belgium

Abstract

Background: Predictive biomarkers for advanced hepatocellular carcinoma are lacking. EZH2 drives sorafenib resistance through H3K27me3 and is counteracted by SETD2, which catalyzes H3K36me3. The authors tested the predictive power of circulating H3K27me3 and H3K36me3 in advanced hepatocellular carcinoma patients treated with sorafenib. Methods: A total of 80 plasma samples were tested for histone variants by ELISA. Changes from baseline to best response or progressive disease were correlated with patient survival. Results: A higher EZH2/ SETD2 ratio predicted worse prognosis in this setting. H3K27me3 and H3K36me3 decreased from baseline to best response. The H3K27me3/H3K36me3 ratio increased from baseline to progressive disease. Higher ratios at best response were associated with shorter progression-free survival. Conclusion: The authors suggest that circulating H3K27me3/H3K36me3 ratio level acts as a predictive biomarker for sorafenib treatment outcomes in patients with advanced hepatocellular carcinoma.

Funder

Higher Education Innovation Fund grant for industrial collaboration

University of Pisa

Publisher

Future Medicine Ltd

Subject

Cancer Research,Genetics

Link

https://www.futuremedicine.com/doi/pdf/10.2217/epi-2021-0383

Reference42 articles.

1. Epidemiology and surveillance for hepatocellular carcinoma: New trends

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries